メニュー
orthogonal1920x640
Application Note

Alpha technology: a fast and sensitive orthogonal approach to cell-based potency assays

Orthogonal systems to cell-based assays are a key requirement in EMA/FDA guidelines for potency estimations and require cross-validation with complementary approaches to prove and strengthen the reliability of results.

In this application note published in collaboration with IBR Inc., you will learn:

  • Why Alpha technology represents an ideal cell-free orthogonal system for potency assays
  • How AlphaLISA assays can be used to determine Bevacizumab/VEGF165 potency
  • An example of how to run an AlphaLISA potency assay and the type of data that can be generated
  • Why it is suitable for assessing lot-to-lot consistency and equivalence of Bevacizumab and biosimilars

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Download Resource

Alpha technology: a fast and sensitive orthogonal approach to cell-based potency assays

Download Application Note